Literature DB >> 11930314

Is human immunodeficiency virus RNA load composed of neutralized immune complexes?

Ferdinando Dianzani1, Guido Antonelli, Elisabetta Riva, Ombretta Turriziani, Laura Antonelli, Stephen Tyring, Daniel A Carrasco, Hung Lee, Derrick Nguyen, Jingzhi Pan, Joyce Poast, Miles Cloyd, Samuel Baron.   

Abstract

During acute human immunodeficiency virus (HIV) infection, both virus load (HIV RNA) and infectivity are high (10(3)-10(7) RNA copies/mL or TCID(50)/mL) until antibody is produced, which may reduce the HIV infectivity. In HIV carriers, the HIV RNA load is elevated (10(3)-10(5) copies/mL), but infectivity is low (10(0)-10(2) TCID(50)/mL). The low infectivity in carriers could be due to neutralization by antibody in serum, resulting in immune complexes (ICs). We demonstrated that ICs in plasma, prepared with protein A beads, contained HIV RNA (80%-100%) in association with immunoglobulin G (IgG). In comparison, ICs from patients with acute HIV infection and little or no antibody contained virtually no HIV RNA. Moreover, ICs prepared by ultrafiltration contained IgG and specifically and irreversibly neutralized HIV, which indicates that the ICs contained neutralizing antibody. These findings indicate that the HIV RNA in the plasma of carriers is frequently composed of antibody-neutralized HIV as ICs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11930314     DOI: 10.1086/340043

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection.

Authors:  Pinghuang Liu; R Glenn Overman; Nicole L Yates; S Munir Alam; Nathan Vandergrift; Yue Chen; Frederik Graw; Stephanie A Freel; John C Kappes; Christina Ochsenbauer; David C Montefiori; Feng Gao; Alan S Perelson; Myron S Cohen; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

2.  Simian immunodeficiency virus (SIV)/immunoglobulin G immune complexes in SIV-infected macaques block detection of CD16 but not cytolytic activity of natural killer cells.

Authors:  Qing Wei; Jackie W Stallworth; Patricia J Vance; James A Hoxie; Patricia N Fultz
Journal:  Clin Vaccine Immunol       Date:  2006-07

3.  Immune complexed (IC) hepatitis C virus (HCV) in chronically and acutely HCV-infected patients.

Authors:  E Riva; F Maggi; F Abbruzzese; F Bellomi; G Giannelli; A Picardi; C Scagnolari; A Folgori; E Spada; E Piccolella; F Dianzani; G Antonelli
Journal:  Med Microbiol Immunol       Date:  2008-08-12       Impact factor: 3.402

4.  Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.

Authors:  Georgia D Tomaras; Nicole L Yates; Pinghuang Liu; Li Qin; Genevieve G Fouda; Leslie L Chavez; Allan C Decamp; Robert J Parks; Vicki C Ashley; Judith T Lucas; Myron Cohen; Joseph Eron; Charles B Hicks; Hua-Xin Liao; Steven G Self; Gary Landucci; Donald N Forthal; Kent J Weinhold; Brandon F Keele; Beatrice H Hahn; Michael L Greenberg; Lynn Morris; Salim S Abdool Karim; William A Blattner; David C Montefiori; George M Shaw; Alan S Perelson; Barton F Haynes
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

5.  Detection of infectious human immunodeficiency virus type 1 in female genital secretions by a short-term culture method.

Authors:  James E Cummins; Julie M Villanueva; Tammy Evans-Strickfaden; Shekou M Sesay; Sheila R Abner; Timothy J Bush; Timothy A Green; Jeffrey L Lennox; Thomas Wright; Thomas M Folks; Clyde E Hart; Charlene S Dezzutti
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

6.  Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection.

Authors:  Naveen K Vaidya; Ruy M Ribeiro; Pinghuang Liu; Barton F Haynes; Georgia D Tomaras; Alan S Perelson
Journal:  Front Microbiol       Date:  2018-06-20       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.